Isabelle De Crémoux

Biography

 Isabelle de Cremoux is the President and CEO of Seventure Partners and manages the Life Sciences team. Seventure Partners is a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices, industrial biotechnologies/cleantech and nutrition. The specific ‘core’ of Seventure’s investment strategy is ‘nutrition, health and wellness’, with particular focus on the intestinal microbiome. Formerly, Isabelle started her career in ’91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development. Since ’98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the life sciences department. Isabelle leads the life sciences team and makes direct investments, mainly in France and Scandinavia with a focus on biotech, nutrition, personalized medicine and especially microbiome. Isabelle’s trackrecord includes Santaris (sold to Roche for $450 millions in august 2014), argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience.

Research Interest

Therapeutics, medical devices, industrial biotechnologies/cleantech and nutrition.